Scholarlink

Background <p>This study aimed to externally validate the CaRdiac Arrest Survival Score (CRASS) for predicting good neurological outcomes in Asian patients with out-of-hospital cardiac arrest (OHCA), focusing on cardiac-origin and noncardiac-origin cohorts, respectively.</p> Methods <p>This multicenter retrospective cohort study, conducted from January 2016 to December 2023 across three hospitals in Taiwan, included patients with OHCA with resuscitation attempts, and excluded those with trauma-related arrests, pediatric cases, or missing data. The CRASS score was calculated for each patient according to the clinical variables at presentation. The outcome involves a good neurological outcome (Cerebral Performance Category (CPC) 1 or 2) at hospital discharge. Predictive performance was evaluated using the area under the receiver operating characteristic curve (AUROC), calibration plots, and other performance metrics, including sensitivity, specificity, and positive and negative predictive values.</p> Results <p>This study analyzed 1,311 patients with OHCA (667 cardiac-origin and 644 noncardiac-origin). The AUROC for predicting good neurological outcomes was 0.770 (95% confidence interval [CI]: 0.733–0.807) in the cardiac-origin cohort compared with 0.729 (95% CI: 0.661–0.796) in the noncardiac-origin cohort. The CRASS score exhibited better predictive performance in patients with cardiac origin, with an optimal cut-off value of 1.45, thereby supporting more aggressive treatment. The score in patients with noncardiac origin was more effective in predicting poor neurological outcomes, with an optimal cut-off value of − 1.47, favoring life support withdrawal.</p> Conclusions <p>The CRASS score is effective for predicting good neurological outcomes in patients with cardiac-origin OHCA but is more suited to guiding treatment withdrawal in noncardiac-origin cases.</p> Clinical trial number <p>Not applicable.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

External validation of the CRASS score for predicting good neurological outcome in out-of-hospital cardiac arrest: analysis from cardiac-origin and non-cardiac origin cohorts

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月16日

查看全文
  • Chih-Wei Sung,
  • Ching-Yu Chen,
  • Cheng-Yi Fan,
  • Yi-Chien Kuo,
  • Chun-Hsiang Huang,
  • Sih-Shiang Huang,
  • Chi-Hsin Chen,
  • Chien-Tai Huang,
  • Yi-Ju Ho,
  • Chun-Ju Lien,
  • Wei-Tien Chang,
  • Edward Pei-Chuan Huang

摘要

Background

This study aimed to externally validate the CaRdiac Arrest Survival Score (CRASS) for predicting good neurological outcomes in Asian patients with out-of-hospital cardiac arrest (OHCA), focusing on cardiac-origin and noncardiac-origin cohorts, respectively.

Methods

This multicenter retrospective cohort study, conducted from January 2016 to December 2023 across three hospitals in Taiwan, included patients with OHCA with resuscitation attempts, and excluded those with trauma-related arrests, pediatric cases, or missing data. The CRASS score was calculated for each patient according to the clinical variables at presentation. The outcome involves a good neurological outcome (Cerebral Performance Category (CPC) 1 or 2) at hospital discharge. Predictive performance was evaluated using the area under the receiver operating characteristic curve (AUROC), calibration plots, and other performance metrics, including sensitivity, specificity, and positive and negative predictive values.

Results

This study analyzed 1,311 patients with OHCA (667 cardiac-origin and 644 noncardiac-origin). The AUROC for predicting good neurological outcomes was 0.770 (95% confidence interval [CI]: 0.733–0.807) in the cardiac-origin cohort compared with 0.729 (95% CI: 0.661–0.796) in the noncardiac-origin cohort. The CRASS score exhibited better predictive performance in patients with cardiac origin, with an optimal cut-off value of 1.45, thereby supporting more aggressive treatment. The score in patients with noncardiac origin was more effective in predicting poor neurological outcomes, with an optimal cut-off value of − 1.47, favoring life support withdrawal.

Conclusions

The CRASS score is effective for predicting good neurological outcomes in patients with cardiac-origin OHCA but is more suited to guiding treatment withdrawal in noncardiac-origin cases.

Clinical trial number

Not applicable.